{"id":1903,"date":"2021-02-24T13:11:16","date_gmt":"2021-02-24T13:11:16","guid":{"rendered":"https:\/\/meditrial.net\/clinical-trials-where\/?page_id=1903"},"modified":"2022-07-07T18:15:08","modified_gmt":"2022-07-07T18:15:08","slug":"lithuania","status":"publish","type":"page","link":"https:\/\/meditrial.net\/clinical-trials-where\/eastern-europe\/lithuania\/","title":{"rendered":"Lithuania"},"content":{"rendered":"
<\/span><\/div>

Lithuanian Approval Process<\/h2>\n

Lithuania joined the EU in 2004 and since then harmonized the legislation on clinical trials with the EU, implemented Directives into the local regulations, and also started to follow the applicable EU guidelines.
\nResearch start-up time: 3.5 \u2013 4 months.<\/p>\n

Lithuanian Recruitment Potential<\/h2>\n

Lithuania is a very attractive country for clinical trials because it offers access to a large group of patients who have not yet been treated with modern pharmaceuticals or devices (mainly due to economic limitations). Therefore, large patient groups are available in all major therapeutic areas.
\nMoreover, Lithuania offers a relatively short study start-up period, which makes it an excellent place to conduct \u201cfirst-in-man\u201d research.
\nOver the last two years, in Belarus about 180 studies were conducted mainly focusing on oncology, cardiology and diabetes.<\/p>\n

Investigators and Sites<\/h2>\n

There are approximately 145 sites in Lithuania, mainly public hospitals and outpatient clinics. Sites are properly equipped and procedures are conducted according to the European standard of care.
\nInvestigators are ICH GCP experienced and well educated.<\/p>\n<\/div><\/div>